Precision BioSciences Welcomes Fayaz Khazi, Ph.D. as President of PlantSciences

DURHAM, N.C.–(BUSINESS WIRE)–Precision
BioSciences
has appointed Fayaz Khazi, Ph.D., to serve as the
President of Precision PlantSciences, a business unit developing
innovative, high impact products in the food and agriculture sectors
aligned with Precision’s overall mission to improve life through
scientific innovation.

“I am thrilled to welcome Fayaz Khazi to the Precision team,” said
Matthew Kane, Chief Executive Officer of Precision BioSciences. “It was
essential that we find a leader with demonstrated success in both
agricultural innovation and human health and, more importantly, someone
who could appreciate the critical connections between the two. With his
unique expertise and vision, I am convinced that Fayaz will lead us
beyond traditional crop enhancements and develop truly novel products
that bridge human health and industry demands.”

Prior to joining Precision, Dr. Khazi was the Chief Executive Officer of
KeyGene USA. At KeyGene, Fayaz established highly successful business
relationships and strategic R&D collaborations to enable accelerated
crop improvement in the plant breeding, food ingredients and sustainable
commodities markets in North and South America.

Dr. Khazi holds a doctorate in molecular genetics from Auburn University
where he studied DNA repair and recombination. As an HHMI post-doctoral
fellow, he trained with Dr. Katherine High at The Children’s Hospital of
Philadelphia studying genotoxicity of gene therapy vectors and
developing in vivo genome-editing technologies to treat hemophilia B. He
then became the founding Director of Translational Medicine at Intrexon
Corporation, where he held several executive leadership positions
supporting the food, human health and agricultural biotechnology
sectors. Dr. Khazi also worked with executive management at Intrexon to
help launch a successful IPO in 2013 (NYSE: XON) before moving on to
become Chief Executive Officer of KeyGene USA. With Precision’s next-gen
ARCUS genome-editing platform, Fayaz will continue to pursue innovative
approaches and creative partnerships at the nexus of food, agriculture
and human wellness.

“Technology and scientific innovation are no longer limitations to fully
addressing generational challenges of nutritional security and wellness.
Precision’s technical capabilities and forward-thinking view of the
connections between medicine, nutrition and agriculture are what
attracted me to embark on this journey,” said Fayaz. “Through innovative
integration of Precision’s ARCUS genome-editing platform with novel
tools in target discovery and validation, we look forward to making a
positive impact on improving global food and nutrition systems,
sustainability and human wellness.”

About Precision BioSciences

Precision BioSciences is a genome editing company dedicated to improving
life. Our team seeks to solve significant problems in oncology, genetic
disease, agriculture, and beyond using a unique, proprietary
genome-editing platform called ARCUS. With an industry-leading
combination of site specificity, ease of delivery, and breadth of
targeting and editing capabilities, our next-gen editing approach
overcomes major challenges limiting the translation of promising basic
research to products that can fundamentally improve life.

Contacts

Precision BioSciences
Heather King, +1-919-314-5512
heather.king@precisionbiosciences.com